Hematology & Oncology Specialists (4228 Houma Blvd., Metairie, 883-2960) is enrolling patients in a global clinical trial to evaluate an investigational treatment for women whose platinum-sensitive ovarian cancer has recurred. Patients interested in participating in the study should call 885-8220.
Sponsored by the biopharmaceutical company Morphotek Inc., the FAR-131 study will evaluate whether the monoclonal antibody farletuzumab can block the protein involved in the growth of tumor cells in these patients. The trial will determine whether the drug can prolong remission in women who have relapsed after six months from their last cancer treatment.
Morphotek wants to enroll as many as 900 patients in the study, which will be conducted at sites in Asia, Australia, Europe, and South and North America, including Hematology and Oncology Specialists. — Kandace Power Graves